Outcomes of allogeneic hematopoietic stem cell transplantation for lymphomas: a single-institution experience

Mira Romany Massoud , Paolo Fabrizio Caimi , Nicole Ferrari , Pingfu Fu , Richard Creger , Robert Fox , Joanne Carlson-Barko , Merle Kolk , Lauren Brister , Brenda Wimpfheimer Cooper , Stanton Gerson , Hillard Michael Lazarus , Marcos de Lima , Basem Magdy William
{"title":"Outcomes of allogeneic hematopoietic stem cell transplantation for lymphomas: a single-institution experience","authors":"Mira Romany Massoud ,&nbsp;Paolo Fabrizio Caimi ,&nbsp;Nicole Ferrari ,&nbsp;Pingfu Fu ,&nbsp;Richard Creger ,&nbsp;Robert Fox ,&nbsp;Joanne Carlson-Barko ,&nbsp;Merle Kolk ,&nbsp;Lauren Brister ,&nbsp;Brenda Wimpfheimer Cooper ,&nbsp;Stanton Gerson ,&nbsp;Hillard Michael Lazarus ,&nbsp;Marcos de Lima ,&nbsp;Basem Magdy William","doi":"10.1016/j.bjhh.2016.07.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Allogeneic hematopoietic stem cell transplantation offers the opportunity for extended survival in patients with Hodgkin's and non-Hodgkin lymphomas who relapsed after, or were deemed ineligible for, autologous transplantation. This study reports the cumulative experience of a single center over the past 14 years aiming to define the impact of patient, disease, and transplant-related characteristics on outcomes.</p></div><div><h3>Methods</h3><p>All patients with histologically confirmed diagnosis of Hodgkin's or non-Hodgkin lymphomas who received allogeneic transplantation from 2000 to 2014 were retrospectively studied.</p></div><div><h3>Results</h3><p>Forty-one patients were reviewed: 10 (24%) had Hodgkin's and 31 (76%) had non-Hodgkin lymphomas. The median age was 50 years and 23 (56%) were male. The majority of patients (68%) had had a prior autologous transplantation. At the time of allogeneic transplantation, 18 (43%) patients were in complete and seven (17%) were in partial remission. Most (95%) patients received reduced-intensity conditioning, 49% received matched sibling donor grafts, 24% matched-unrelated donor grafts, and 27% received double umbilical cord blood grafts. The 100-day treatment-related mortality rate was 12%. After a median duration of follow up of 17.1 months, the median progression-free and overall survival was 40.5 and 95.8 months, respectively. On multivariate analysis, patients who had active disease at the time of transplant had inferior survival.</p></div><div><h3>Conclusions</h3><p>Allogeneic transplantation results extend survival in selected patients with relapsed/refractory Hodgkin's and non-Hodgkin lymphomas with low treatment-related mortality. Patients who have active disease at the time of allogeneic transplantation have poor outcomes.</p></div>","PeriodicalId":21233,"journal":{"name":"Revista Brasileira de Hematologia e Hemoterapia","volume":"38 4","pages":"Pages 314-319"},"PeriodicalIF":0.0000,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bjhh.2016.07.003","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Brasileira de Hematologia e Hemoterapia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1516848416300743","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Introduction

Allogeneic hematopoietic stem cell transplantation offers the opportunity for extended survival in patients with Hodgkin's and non-Hodgkin lymphomas who relapsed after, or were deemed ineligible for, autologous transplantation. This study reports the cumulative experience of a single center over the past 14 years aiming to define the impact of patient, disease, and transplant-related characteristics on outcomes.

Methods

All patients with histologically confirmed diagnosis of Hodgkin's or non-Hodgkin lymphomas who received allogeneic transplantation from 2000 to 2014 were retrospectively studied.

Results

Forty-one patients were reviewed: 10 (24%) had Hodgkin's and 31 (76%) had non-Hodgkin lymphomas. The median age was 50 years and 23 (56%) were male. The majority of patients (68%) had had a prior autologous transplantation. At the time of allogeneic transplantation, 18 (43%) patients were in complete and seven (17%) were in partial remission. Most (95%) patients received reduced-intensity conditioning, 49% received matched sibling donor grafts, 24% matched-unrelated donor grafts, and 27% received double umbilical cord blood grafts. The 100-day treatment-related mortality rate was 12%. After a median duration of follow up of 17.1 months, the median progression-free and overall survival was 40.5 and 95.8 months, respectively. On multivariate analysis, patients who had active disease at the time of transplant had inferior survival.

Conclusions

Allogeneic transplantation results extend survival in selected patients with relapsed/refractory Hodgkin's and non-Hodgkin lymphomas with low treatment-related mortality. Patients who have active disease at the time of allogeneic transplantation have poor outcomes.

同种异体造血干细胞移植治疗淋巴瘤的结果:单一机构的经验
同种异体造血干细胞移植为霍奇金淋巴瘤和非霍奇金淋巴瘤患者提供了延长生存期的机会,这些患者在自体移植后复发或被认为不适合自体移植。本研究报告了过去14年来单个中心的累积经验,旨在确定患者、疾病和移植相关特征对结果的影响。方法回顾性分析2000 ~ 2014年所有经组织学证实的霍奇金淋巴瘤或非霍奇金淋巴瘤行同种异体移植的患者。结果41例患者中,10例(24%)为霍奇金淋巴瘤,31例(76%)为非霍奇金淋巴瘤。中位年龄为50岁,其中23例(56%)为男性。大多数患者(68%)之前有过自体移植。同种异体移植时,18例(43%)患者完全缓解,7例(17%)患者部分缓解。大多数(95%)患者接受了低强度调节,49%接受了匹配的兄弟姐妹供体移植,24%接受了匹配的非亲属供体移植,27%接受了双脐带血移植。100天的治疗相关死亡率为12%。中位随访时间为17.1个月,中位无进展生存期和总生存期分别为40.5个月和95.8个月。在多变量分析中,移植时患有活动性疾病的患者生存率较低。结论sallogenic移植结果延长了复发/难治性霍奇金淋巴瘤和非霍奇金淋巴瘤患者的生存期,治疗相关死亡率低。异体移植时患有活动性疾病的患者预后较差。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
21 weeks
期刊介绍: A Revista Brasileira de Hematologia e Hemoterapia é um periódico científico de propriedade da Associação Brasileira de Hematologia e Hemoterapia, publicada bimestralmente. A abreviatura de seu título é Rev. Bras. Hematol. Hemoter., que deve ser usada em bibliografias, notas de rodapé e em referências e legendas bibliográficas.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信